Education
About Us
Working with TipRanks
Follow Us
Immutep (IMMP)
NASDAQ:IMMP
IMMP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.32 - $3.34
Previous CloseN/A
Volume50.42K
Average Volume (3M)85.45K
Market Cap
$220.59M
Enterprise Value$124.09M
Total Cash (Recent Filing)AU$11.02M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Aug 27, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding146,038,960
10 Day Avg. Volume115,380
30 Day Avg. Volume85,451
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$12.00Price Target Upside705.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Immutep News
PremiumCompany Announcements
Immutep Reports Increased Revenue Amid Growing R&D Costs
PremiumCompany Announcements
Immutep Reports Increased Revenue Amid Rising R&D Costs
PremiumCompany Announcements
Immutep Advances to Phase III with Key Approvals and Promising Trial Results
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe combination of efti and Keytruda has demonstrated a promising 67% 12-month overall survival rate, significantly higher than historical results for Keytruda monotherapy.
Market OpportunityThe TACTI-004 trial targets a broad NSCLC setting, potentially opening a large market opportunity for Immutep's efti.
Bears Say
Safety ConcernsThe first-in-human P1 trial for IMP761 is progressing cautiously, with safety being a critical factor for advancement.
Trial ChallengesThe success of the TACTI-004 trial is critical for Immutep, as it is pivotal for opening large market opportunities.
---
Ownership Overview
―
Insiders
0.02% Mutual Funds
0.58% Other Institutional Investors
98.92% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMMP FAQ
What was Immutep’s price range in the past 12 months?
Immutep lowest stock price was $1.32 and its highest was $3.33 in the past 12 months.
What is Immutep’s market cap?
Immutep’s market cap is $220.59M.
When is Immutep’s upcoming earnings report date?
Immutep’s upcoming earnings report date is Aug 27, 2025 which is in 134 days.
How were Immutep’s earnings last quarter?
Immutep released its earnings results on Feb 26, 2025. The company reported -$0.096 earnings per share for the quarter, beating the consensus estimate of -$0.136 by $0.04.
Is Immutep overvalued?
According to Wall Street analysts Immutep’s price is currently Undervalued.
Does Immutep pay dividends?
Immutep does not currently pay dividends.
What is Immutep’s EPS estimate?
Immutep’s EPS estimate is -0.13.
How many shares outstanding does Immutep have?
Immutep has 146,038,960 shares outstanding.
What happened to Immutep’s price movement after its last earnings report?
Immutep reported an EPS of -$0.096 in its last earnings report, beating expectations of -$0.136. Following the earnings report the stock price went up 1.064%.
Which hedge fund is a major shareholder of Immutep?
Currently, no hedge funds are holding shares in IMMP
---
Immutep Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (705.37% Upside)
$12.00 (705.37% Upside)
Blogger Sentiment
Bullish
IMMP Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 564.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.29%
12-Months-Change
Fundamentals
Return on Equity
-31.16%
Trailing 12-Months
Asset Growth
33.65%
Trailing 12-Months
Company Description
Immutep
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
---
IMMP Stock 12 Month Forecast
Average Price Target
$12.00
▲(705.37% Upside)
Technical Analysis
Astria Therapeutics
―
Y-Mabs Therapeutics
―
iTeos Therapeutics
―
Atea Pharmaceuticals
―
Compass Therapeutics
―
Best Analysts Covering IMMP
1 Year
1 Year Success Rate
0/11 ratings generated profit
1 Year Average Return
-42.80%
reiterated a buy rating 7 months ago
Copying Naureen Quibria's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -42.80% per trade.
---